UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) in psoriatic arthritis and axial spondyloarthritis. The results, presented at EULAR 2025, show sustained inflammation control and significant long-term improvements in symptom relief and physical function. Source: Pharmatimes 11/6/2025